Advertisement
Preclinical supplies of the drug substance have been recently secured andthe preclinical development process is being initiated. ChampionsBiotechnology intends to test the BPU Agent utilizing its BiomerkTumorgraft(TM) Preclinical Platform. Studies utilizing Biomerk Tumorgraftsare conducted like Phase II clinical trials and leading pharmaceuticalcompanies are utilizing the Platform because it is believed to be morepredictive than traditional preclinical models.
Advertisement
"We believe that our Biomerk Tumorgrafts accurately predict the outcome ofPhase II clinical trials at the early preclinical stage. This provides anenormous advantage versus traditional preclinical models. By testing the BPUAgent against panels of Biomerk Tumorgrafts from several different cancertypes, we should be able to identify the compound's best application, predictthe outcome of Phase II human trials and, if appropriate, discover biomarkersthat may accelerate its clinical development," stated ChampionsBiotechnology's Chief Scientific Officer, Manual Hidalgo, M.D., Ph.D.
Champions Biotechnology's BPU Agent is an antimitotic inhibitor thattargets MAPT (Microtubule-Associated Protein Tau) deficient tumors, a commonfeature of solid tumors (Molecular Cancer Therapeutics, 2007; 6(5): 1509-1516). The Company, in exchange for 550,000 restricted shares of its commonstock, was assigned all the rights in the U.S. and in foreign countries to theapplications for these inhibitors developed at Johns Hopkins University bytheir inventors Drs. Saeed Khan, Gurulingappa Hallur, Manuel Hidalgo andAntonio Jimeno.
For more information regarding Champions Biotechnology's growing businessand recent news, please visit www.championsbiotechnology.com.
About Champions Biotechnology, Inc.
Champions Biotechnology, Inc. is engaged in the development of advancedpreclinical platforms and predictive tumor specific data to enhance andaccelerate the value of oncology drugs. The Company's Preclinical Platform isa novel approach based upon the implantation of primary human tumors in immunedeficient mice followed by propagation of the resulting xenografts (BiomerkTumorgrafts(TM)) in a manner that preserves the biological characteristics ofthe original human tumor. The Company believes that these Tumorgrafts closelyreflect human cancer biology and their response to drugs is more predictive ofclinical outcomes in cancer patients.
Champions Biotechnology leverages its preclinical platform to evaluatedrug candidates and to develop a portfolio of novel therapeutic candidatesthrough pre-clinical trials. As drugs progress through this early stage ofdevelopment, the Company plans to sell, partner or license them topharmaceutical and/or biotechnology companies, as appropriate. The Companyalso offers its predictive preclinical platform and tumor specific data tophysicians for personalized patient care and to companies for evaluation ofoncology drugs and drug candidates in models that integrate prognostic testingwith biomarker discovery.
Champions Biotechnology is dedicated to enhancing preclinical developmenttools, accelerating development and valuation of oncology drugs, and advancingpersonalized treatment with a goal to improve the lives of cancer patientsglobally.
This press release contains "forward-looking statements" (within themeaning of the Private Securities Litigation Act of 1995) that inhere
